MECOM and acute myeloid leukemia: Experimental expression or knock-down of Evi1 in mouse models of AML promoted or delayed myeloid leukemogenesis, respectively12–15, and activation of EVI1 through vector integration caused AML in a gene therapy trial for chronic granulomatous disease16.